These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 14649076)

  • 21. [Can cardiovascular events be prevented by raising HDL cholesterol?].
    Langslet G; Reikvam A
    Tidsskr Nor Laegeforen; 2008 Jun; 128(13):1519-23. PubMed ID: 18587459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-density lipoprotein cholesterol-raising strategies.
    Kuvin JT; Alsheikh-Ali AA; Karas RH
    J Cardiovasc Pharmacol; 2006 Feb; 47(2):196-204. PubMed ID: 16495756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
    Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
    Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug treatment of lipid disorders.
    Knopp RH
    N Engl J Med; 1999 Aug; 341(7):498-511. PubMed ID: 10441607
    [No Abstract]   [Full Text] [Related]  

  • 25. On call. In your January 2007 article on cholesterol, you said that no-flush niacin does not lower cholesterol levels. But my problem is low HDL cholesterol. Will no-flush niacin help my HDL even if it won't lower my LDL cholesterol?
    Simon HB
    Harv Mens Health Watch; 2007 Jun; 11(11):7-8. PubMed ID: 17644843
    [No Abstract]   [Full Text] [Related]  

  • 26. Managing dyslipidemia in adults with diabetes.
    Haffner SM
    Manag Care; 2003 Sep; 12(9 Suppl):10-5. PubMed ID: 14535130
    [No Abstract]   [Full Text] [Related]  

  • 27. Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
    Kastelein JJ
    Am J Cardiol; 2005 Nov; 96(9A):20K-27K; discussion 34K-35K. PubMed ID: 16291010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dyslipidaemia in diabetic patients: time for a rethink.
    Shepherd J
    Diabetes Obes Metab; 2007 Sep; 9(5):609-16. PubMed ID: 17697054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention.
    Parhofer KG
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):414-7. PubMed ID: 16151973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of dyslipoproteinemia risk factor. Lipid therapy must become multidimensional].
    MMW Fortschr Med; 2008 Jun; 150(26-27):52-3. PubMed ID: 18681233
    [No Abstract]   [Full Text] [Related]  

  • 32. Beneficial effects of combined treatment with niacin and chromium on the liver of hyperlipemic rats.
    Bolkent S; Yanardag R; Bolkent S; Döger MM
    Biol Trace Elem Res; 2004 Dec; 101(3):219-29. PubMed ID: 15564652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
    Alrasadi K; Awan Z; Alwaili K; Ruel I; Hafiane A; Krimbou L; Genest J
    Am J Cardiol; 2008 Nov; 102(10):1341-7. PubMed ID: 18993152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy for the treatment of dyslipidemia.
    Streja D
    Curr Opin Investig Drugs; 2004 Mar; 5(3):306-12. PubMed ID: 15083597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patients with low levels of high-density lipoprotein cholesterol: to treat or not to treat?
    Tavintharan S; Lim SC; Sum CF
    Singapore Med J; 2005 Oct; 46(10):519-28. PubMed ID: 16172771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies.
    Toth PP
    Am J Cardiol; 2005 Nov; 96(9A):50K-58K; discussion 34K-35K. PubMed ID: 16291015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Powerful HDL booster available OTC.
    Health News; 2005 Apr; 11(4):5. PubMed ID: 15818764
    [No Abstract]   [Full Text] [Related]  

  • 39. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2006 Nov; 98(9):1231-3. PubMed ID: 17056335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
    Ballantyne CM; Davidson MH; McKenney J; Keller LH; Bajorunas DR; Karas RH
    Am J Cardiol; 2008 May; 101(10):1428-36. PubMed ID: 18471454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.